Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 07 November 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1727580

Correction: Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival

This article is a correction to:

  1. Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival

    1. Read original article
Yu ZhangYu ZhangHaixia GuanHaixia GuanXixuan FengXixuan FengMengyan LiuMengyan LiuJinhuan ShaoJinhuan ShaoMengchi LiuMengchi LiuJialei HeJialei HeYahui Jin*Yahui Jin*Jinglin Zhu*Jinglin Zhu*Chunli Zheng*Chunli Zheng*
  • Yan’an Medical College, Yan’an University, Yan’an, Shaanxi, China

A Correction on
Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival

By Zhang Y, Guan H, Feng X, Liu M, Shao J, Liu M, He J, Jin Y, Zhu J and Zheng C (2025) Front. Immunol. 16:1616414. doi: 10.3389/fimmu.2025.1616414

There was a mistake in Table 7 as published. The phases corresponding to NCT06751966 and NCT06751914 were omitted. The corrected Table 7 appears below.

Table 7
www.frontiersin.org

Table 7. Clinical trials based on neoantigen vaccines for the treatment of colorectal cancer.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: colorectal cancer immunotherapy, immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, matrix-depletion therapy

Citation: Zhang Y, Guan H, Feng X, Liu M, Shao J, Liu M, He J, Jin Y, Zhu J and Zheng C (2025) Correction: Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival. Front. Immunol. 16:1727580. doi: 10.3389/fimmu.2025.1727580

Received: 18 October 2025; Accepted: 30 October 2025;
Published: 07 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Zhang, Guan, Feng, Liu, Shao, Liu, He, Jin, Zhu and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chunli Zheng, Y2h1bmxpemhlbmdAMTI2LmNvbQ==; Jinglin Zhu, emh1amluZ2xpbjI3QDE2My5jb20=; Yahui Jin, c3h4YWp5aEAxMjYuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.